Site navigation

Navigation

Acute coronary syndrome - prasugrel

Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention

Status: In progress
Expected date of issue: October 2009
Wave: 17
Process: STA
Topic area:
  • Cardiovascular
 

NICE project team

Executive Lead: Gillian Leng
Technical Lead: Ruaraidh Hill
Communications manager: Phil Ranson
Project manager: Laura Malone
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 09 February 2009
1st appraisal committee meeting: 14 May 2009
Top


 

Stakeholders

Consultees Commentators (no right to submit or appeal)

Manufacturers / Sponsors

  • Eli Lilly & Co (prasugrel)

Patient / carer Groups

  • Action Heart

Professional groups

  • British Cardiovascular Society
  • British Geriatrics Society
  • British Heart Foundation
  • British Institute of Radiology
  • Royal College of Nursing
  • Royal Collegeof Physicians
  • British Atherosclerosis Society

Others

  • Department of Health
  • Welsh Assembly Government

General

  • Department of Health, Social Services and Public Safety for Northern Ireland

Comparator manufacturer(s)

  • Sanofi-Aventis (clopidogrel)
  • Bristol-Myers Squibb Pharmaceuticals (clopidogrel)
  • Daiichi-Sankyo

Relevant research groups

  • None

Evidence Review Group

  • Liverpool Reviews & Implementation Group, University of Liverpool
  • National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme)

Associated Guideline Groups

  • National Collaborating Centre for Chronic Conditions

Associated Public Health Groups

  • None

National organisations wishing to register as a stakeholder can do so via the link below.
Top


 

Key documents

This page was last updated:   16 March 2009